AI must make medicines cheaper to prove its worth
New Delhi, Nov. 15 -- Artificial intelligence is already cutting the time it takes to design new medicines from years to months, oncologist and author Siddhartha Mukherjee said on Saturday, but it must now make medicines faster, cheaper and better for patients if it is to prove its worth.
"The single mitigating feature of AI is its capacity to produce transformative medicine," Mukherjee, co-founder and chief executive of the drug-discovery company Manas AI, said at the 24th edition of the Hindustan Times Leadership Summit.
"Exhibit A of AI's transformative power for human good is medicine. And if we fail in exhibit A, that creates an enormous problem for. whether we put up data centres or not, or what the value is of AI in various other industries."
The harder part, he said, is what happens after a molecule is designed: testing it in people and getting it approved, which have barely changed. AI could speed up clinical trials too, he said, but only with safeguards, so that medicines that do not work are not released to patients.
India, he said, has a "historic opportunity" to show what AI can deliver if it reforms how new drugs are tested and approved.
To lay out his case, Mukherjee explained how arduous drug discovery can be. Every medicine binds to a protein in the body, the way a key fits a lock, he explained. There are 10 to the power of 24 possible small-molecule keys, far too many to try one by one, so modern drug design starts with the lock: find a "keyhole" in the target protein, then build a molecule from scratch to fit it.
This is where AI comes in, he said, citing his company Manas, which combines AI, "which is a neural system", with what it calls "medicinal intelligence": "the rules of physics and chemistry"....
To read the full article or to get the complete feed from this publication, please
Contact Us.